Status:
COMPLETED
DAOIB for the Treatment of Mild Cognitive Impairment
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
50-90 years
Phase:
PHASE2
Brief Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptor-enhancing agent improved the cognitive function of patients with early-phase Alzheimer's disease. This study is a r...
Eligibility Criteria
Inclusion
- Clinical diagnosis of mild cognitive impairment
- MMSE between 17-26
- CDR 0.5
Exclusion
- Hachinski Ischemic Score \> 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major psychiatric disorders
- Major physical illnesses
- Severe visual or hearing impairment
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT04736355
Start Date
January 1 2020
End Date
June 30 2024
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886